Study of a liver-protecting medicine with CAR-T cell therapy for large B-cell lymphoma
Part of Cancer, Immune system & allergy clinical trials.
This study tests whether adding an oral medicine called diammonium glycyrrhizinate (a liver-protecting agent) to CAR-T cell therapy can reduce side effects and improve treatment outcomes for people with large B-cell lymphoma. It may help make the treatment safer and more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have large B-cell lymphoma and be scheduled to receive CAR-T cell therapy.
- Your liver, kidney, and heart function must be within acceptable limits (e.g., liver enzymes not too high, kidney function adequate, heart pumping well).
- You must not have lymphoma in the brain or spinal cord.
- If you are of childbearing age, you must agree to use effective contraception.
- You must be willing and able to give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a drug called emapalumab can reduce serious side effects from CAR-T cell therapy, a treatment for large B-cell lymphoma that has come back or not responded to earlier treatments. If you qualify, you would receive emapalumab alongside your CAR-T treatment to help make it safer.
This study looks at factors that predict how well CAR-T therapy works for large B-cell lymphoma that has come back or not responded to treatment. It aims to help doctors better identify who may benefit from this therapy.
This study looks at adding a supplement called beta-hydroxybutyrate (BHB) to standard CAR-T therapy for people with large B-cell lymphoma. It may help improve how well the treatment works.
This study looks at how the standard chemotherapy given before CAR T-cell therapy affects the treatment's success in people with large B-cell lymphoma that has come back or not responded to previous treatment. It may help doctors find the best way to prepare your body for CAR T-cells.
This trial tests a combination of two immunotherapy drugs (rimegepant and glofitamab) plus a special cell therapy called CD19 CAR-T for people with large B-cell lymphoma that has not responded to or has returned after previous treatment. The goal is to see if this combination can better control the lymphoma and improve outcomes.
This trial tests a combination of two drugs, tafasitamab and lenalidomide, as a first follow-up treatment for people with large B-cell lymphoma that did not fully go away after CAR-T therapy. The goal is to see if this drug pair can help shrink or control the remaining cancer.
Hear when a new Patients With Large B-cell Lymphoma Receiving CAR-T Cell Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.